Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06002503 · ClinicalTrials.gov registry record · Phase 1
Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection
A Phase 1 study of Vaccine Reaction, sponsored by PharmaJet.
- Active
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06002503 is a Phase 1 study of Vaccine Reaction that is active but no longer recruiting, run by PharmaJet. The registered enrollment target is 46 participants, below the 132-participant average among 4 other Vaccine Reaction trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06002503, a Phase 1 study of Vaccine Reaction, is active but no longer recruiting, sponsored by PharmaJet.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the safety and reactogenicity of a VEE DNA Vaccine candidate delivered by either intramuscular or intradermal jet injection. The main question it aims to answer is: • Is the VEE DNA Vaccine candidate safe Participants will: * Receive the VEE DNA Vaccine candidate by either intramuscular or intradermal jet injection * Provide blood and urine samples * Complete ECGs * Complete physical exams * Complete diaries
Conditions Studied
Interventions
- DRUG Venezuelan Equine Encephalitis DNA Vaccine
- DEVICE PharmaJet Stratis Needle-free Injection System
- DEVICE PharmaJet Tropis Needle-free Injection System
Study Locations (1)
Ohio
- Velocity Clinical Research - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2023-10-16 |
| Est. Completion | 2025-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06002503
The ClinicalTrials.gov registry entry for NCT06002503 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 4 other Vaccine Reaction trials with a reported enrollment target (65% lower). The listed sponsor is PharmaJet, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vaccine Reaction appearing as the primary indexed condition, and to 3 interventions - of which Venezuelan Equine Encephalitis DNA Vaccine is the first listed.
NCT06002503 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06002503 about?
NCT06002503 is a clinical study titled "Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection". The goal of this clinical trial is to evaluate the safety and reactogenicity of a VEE DNA Vaccine candidate delivered by either intramuscular or intradermal jet injection. The main question it aims to answer is: • Is the VEE DNA Vaccine candidate safe Participants will: * Receive the VEE DNA Vacc...
What is the current status of trial NCT06002503?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2023-10-16. Estimated completion is 2025-05-31.
What conditions does trial NCT06002503 study?
This clinical trial studies the following conditions: Vaccine Reaction.
What interventions are being tested in trial NCT06002503?
The interventions under investigation include: Venezuelan Equine Encephalitis DNA Vaccine (DRUG), PharmaJet Stratis Needle-free Injection System (DEVICE), PharmaJet Tropis Needle-free Injection System (DEVICE).
Who is sponsoring clinical trial NCT06002503?
This trial is sponsored by PharmaJet, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06002503 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaccine Reaction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intradermal Influenza Vaccination
RECRUITING · Early Phase 1
-
Understanding Poor Vaccine Responses to Hepatitis B Vaccination
ACTIVE NOT RECRUITING · Phase 4
-
Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients
COMPLETED
-
Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.